Moleculin Gets FDA Fast-Track Designation for WP1122 in Glioblastoma Multiforme

By Colin Kellaher

Moleculin Biotech Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to its WP1122 pipeline candidate for the treatment of glioblastoma multiforme, the most aggressive malignant primary brain tumor.

The Houston clinical-stage pharmaceutical company said it is currently evaluating opportunities for collaboration in clinical development of WP1122.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

In September, Moleculin said it received FDA orphan-drug designation for WP1122 in glioblastoma multiforme.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

12-07-22 0913ET